Aptorum Group Limited (APM): Elevating into Neurodiagnostics Through Strategic Merger & Regulatory Approval

Overview
Aptorum Group Limited (NASDAQ: APM), a clinical-stage biopharmaceutical firm with a focus on oncology, infectious diseases, and diagnostics initiatives, is undergoing a transformative pivot. Today’s headlines center on its definitive merger agreement with DiamiR Biosciences—coupled with a recent regulatory milestone—that positions the combined company to lead in neurodiagnostics and Alzheimer’s testing.

Merger with DiamiR: A Catalyst for Strategic Expansion

Aptorum recently finalized an all-stock merger agreement with DiamiR Biosciences, a company that operates a CLIA-licensed, CAP-accredited lab in New Haven, Connecticut. DiamiR brings to the table a proprietary platform of blood-based microRNA tests designed for early detection and monitoring of neurodegenerative diseases, including Alzheimer’s and Parkinson’s. This merger will transform Aptorum into a diversified biopharma and diagnostic powerhouse, capable of monetizing services immediately upon close.Investing.com+13AInvest+13Stock Titan+13

Regulatory Approval: New York State OKs APOE Genotyping Test

In a further boost to credibility and market readiness, Aptorum and DiamiR have announced that New York State has approved DiamiR’s APOE genotyping test, a key biomarker test for Alzheimer’s risk. This approval unlocks access to a massive diagnostics market and elevates the combined firm’s market potential significantly.manilatimes.net+1

Why Investors Should Watch APM

SCN Take

The Aptorum–DiamiR merger represents a compelling growth angle: combining therapeutics with high-value diagnostics in neurodegenerative disease. With regulatory validation underway (including CLIA/CAP licensing and NY approval) and a clear path to revenue, Aptorum now stands out in precision medicine innovation.

Retail investors with a high-risk tolerance and long-term horizon may find APM attractive as it positions itself at the intersection of diagnostics and life sciences.

Let SCN know if you’d like a deep dive into DiamiR’s microRNA platform or competitive landscape in Alzheimer’s diagnostics!